EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer

Ciara Conduit, Jeremy Lewin iD, Wei Hong, Ie-Wen Sim, Gulfam Ahmad, Matt Leonard, Sophie O'Haire, Mary Moody, Amanda D Hutchinson iD, Nathan Lawrentschuk iD, Benjamin Thomas iD, Haryana M Dhillon und 1 weitere

BJU International · 2024

DOI: 10.1111/bju.16481 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJU International, 2024. Verfasst von Ciara Conduit und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Testicular Neoplasms, Lymph Node Excision, Ejaculation, Quality of Life. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the impact of ejaculatory dysfunction (EjD; failure of emission or retrograde ejaculation) on health‐related quality of life (HRQoL) after retroperitoneal lymph node dissection (RPLND) for testicular cancer and explore the efficacy of pseudoephedrine hydrochloride as treatment. Patients and Methods In a single arm, phase II trial, patients at ≥6 months after RPLND were invited to complete patient‐reported outcome measures (European Organisation for Research and Treatment of Cancer [EORTC] quality of life questionnaire [QLQ]‐30‐item core, EORTC QLQ‐testicular cancer‐26, and Brief Male Sexual Function Inventory) evaluating HRQoL and sexual function in follow‐up (ACTRN12622000537752/12622000542796). If EjD was reported, post‐ejaculatory urine ± semen analysis was undertaken. In eligible patients, pseudoephedrine hydrochloride 60 mg was administered orally every 6 h for six doses. The primary endpoint was sperm count >39 million sperm/ejaculate (>5th centile) following treatment. The trial was powered to detect a clinically relevant 36% achieving sperm count of >39 million sperm/ejaculate. Secondary endpoints included semen volume >1.5 mL, total motile sperm count, safety, and HRQoL impacts.

Results

Of the 58 patients enrolled, the median (interquartile range [IQR]) age was 35 (29–41) years, with a median (IQR) of 37 (18–60) months from RPLND. EjD was reported in 33 (57%), including 27/52 (52%) receiving follow‐up at our centre. There were no differences in global HRQoL; however, role functioning ( P = 0.045), sexual problems ( P < 0.005), and sexual enjoyment ( P = 0.005) was poorer if EjD was present. In all, 24/33 (73%) patients with EjD consented to pseudoephedrine treatment. Of 22 evaluable patients, four (18%) achieved a sperm count of >39 million/ejaculate ( P = 0.20), and four (18%) had a semen volume of >1.5 mL ( P = 0.20). There was a mean increase of 105 million sperm/ejaculate ( P = 0.051) and 1.47 mL increase in semen volume ( P = 0.01). No safety concerns arose.

Conclusion

Ejaculatory dysfunction is common after RPLND but did not impact global HRQoL in our cohort. Pseudoephedrine improved EjD for some; however, its efficacy was lower than expected. Pseudoephedrine may be considered on an individualised basis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsLymph Node ExcisionEjaculationQuality of LifePseudoephedrineSexual Dysfunction, PhysiologicalMaleHumansAdultRetroperitoneal SpaceMiddle AgedPatient Reported Outcome MeasuresSperm CountEjaculatory Dysfunction

Stichwörter der Autor:innen

ejaculationfertilityhealth‐related quality of lifesurvivortesticular cancer

Substanzen

Pseudoephedrine

Autor:innen und Institutionen

  • Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
  • Victorian Adolescent and Young Adult Cancer Service, Melbourne, Victoria, Australia.
  • Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Jeremy Lewin, Amanda D Hutchinson, Nathan Lawrentschuk, Benjamin Thomas

Zitieren

APA

Conduit, C., Lewin, J., Hong, W., Sim, I. W., Ahmad, G., Leonard, M., O'Haire, S., Moody, M., Hutchinson, A. D., Lawrentschuk, N., Thomas, B., Dhillon, H. M., & Tran, B. (2024). Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer. BJU International. https://doi.org/10.1111/bju.16481

Vancouver

Conduit C, Lewin J, Hong W, Sim IW, Ahmad G, Leonard M, et al. Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer. BJU International. 2024. doi:10.1111/bju.16481

BibTeX
@article{Conduit2024,
  author = {Conduit, Ciara and Lewin, Jeremy and Hong, Wei and Sim, Ie-Wen and Ahmad, Gulfam and Leonard, Matt and O'Haire, Sophie and Moody, Mary and Hutchinson, Amanda D and Lawrentschuk, Nathan and Thomas, Benjamin and Dhillon, Haryana M and Tran, Ben},
  title = {Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16481}
}
Kostenlos starten →